{"id":"c-tb","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109410","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"C-Tb is a subunit vaccine containing recombinant TB antigens (likely including ESAT-6 and CFP-10) designed to boost cellular immunity against tuberculosis. It is intended to be used as a therapeutic vaccine in combination with standard TB chemotherapy to enhance immune clearance of the pathogen and potentially improve treatment outcomes.","oneSentence":"C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:33.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB) as adjunctive therapy with standard anti-TB chemotherapy"}]},"trialDetails":[{"nctId":"NCT06670755","phase":"NA","title":"ID93/GLA-SE Vaccination + BCG Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-12-18","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT04240990","phase":"NA","title":"Development of a Diagnostic Prediction Score for Tuberculosis in Hospitalized Children With Severe Acute Malnutrition (TB-Speed SAM)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-11-04","conditions":"Tuberculosis, Severe Acute Malnutrition","enrollment":603},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT05845112","phase":"","title":"Start Taking Action For TB Diagnosis","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-02-28","conditions":"Diagnosis, Tuberculosis","enrollment":14747},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT04666311","phase":"","title":"Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Klaus Reither","startDate":"2021-02-15","conditions":"Pulmonary Tuberculosis, Tuberculosis Diagnosis, Covid-19","enrollment":1400},{"nctId":"NCT06796647","phase":"","title":"ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-03-19","conditions":"Tuberculosis (TB)","enrollment":100},{"nctId":"NCT07163143","phase":"PHASE3","title":"Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2025-11","conditions":"Tuberculosis (TB)","enrollment":784},{"nctId":"NCT06113861","phase":"","title":"Diagnostic Innovations for Pediatric Tuberculosis in Bolivia","status":"RECRUITING","sponsor":"Tulane University","startDate":"2024-04-15","conditions":"Tuberculosis","enrollment":1220},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":"Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis","enrollment":120},{"nctId":"NCT05027581","phase":"PHASE2","title":"Chondrochymal® for Subjects With Knee Osteoarthritis (Knee OA)","status":"COMPLETED","sponsor":"Taiwan Bio Therapeutics Inc.","startDate":"2021-10-13","conditions":"Osteoarthritis, Knee","enrollment":72},{"nctId":"NCT04557176","phase":"NA","title":"TB Screening Improves Preventive Therapy Uptake","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-11-16","conditions":"Tuberculosis, Latent Tuberculosis, Tuberculosis Prevention","enrollment":1719},{"nctId":"NCT06751706","phase":"","title":"Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2024-09-30","conditions":"Tuberculosis, Latent Tuberculosis","enrollment":60},{"nctId":"NCT05221502","phase":"PHASE2","title":"Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-04-12","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT04568954","phase":"NA","title":"TB-CAPT CORE Truenat Trial","status":"COMPLETED","sponsor":"Foundation for Innovative New Diagnostics, Switzerland","startDate":"2022-08-28","conditions":"Tuberculosis, Diagnoses Disease","enrollment":3987},{"nctId":"NCT06221735","phase":"NA","title":"Evaluating the Accuracy of New Tests for TB Infection Diagnosis","status":"COMPLETED","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2024-06-11","conditions":"Latent Tuberculosis, TB Infection, Tuberculosis","enrollment":352},{"nctId":"NCT05282173","phase":"NA","title":"Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa","status":"COMPLETED","sponsor":"University of Maryland, College Park","startDate":"2022-06-08","conditions":"Substance-Related Disorders, Mental Disorder, Social Stigma","enrollment":82},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT04975178","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Biofabri, S.L","startDate":"2022-10-17","conditions":"Tuberculosis","enrollment":7120},{"nctId":"NCT05655702","phase":"NA","title":"DRug Use & Infections in ViEtnam: TuBerculosis Control","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-10-02","conditions":"Tuberculosis","enrollment":4000},{"nctId":"NCT03044509","phase":"","title":"Diagnosis of Tuberculosis in Swiss Children","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2017-05-12","conditions":"Tuberculosis, Mycobacterium Tuberculosis","enrollment":190},{"nctId":"NCT04309656","phase":"PHASE1","title":"Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2020-01-14","conditions":"Multi-drug Resistant Tuberculosis","enrollment":48},{"nctId":"NCT02821832","phase":"PHASE2","title":"Using Biomarkers to Predict TB Treatment Duration","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-21","conditions":"Pulmonary Tuberculosis","enrollment":946},{"nctId":"NCT06307171","phase":"NA","title":"Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers","status":"RECRUITING","sponsor":"IRCCS Sacro Cuore Don Calabria di Negrar","startDate":"2023-05-22","conditions":"Leishmaniasis","enrollment":170},{"nctId":"NCT05472051","phase":"","title":"Health and Migration Trajectories of Housekeepers in Bamako","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-02-28","conditions":"HIV Infections, Hepatitis B, Hepatitis C","enrollment":644},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT03474198","phase":"PHASE2, PHASE3","title":"Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-21","conditions":"Tuberculosis, Pulmonary","enrollment":675},{"nctId":"NCT03174184","phase":"PHASE2","title":"Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-08-23","conditions":"Tuberculosis, Pulmonary","enrollment":112},{"nctId":"NCT04241809","phase":"","title":"Bioaerosol Sampling in Suspected Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Desmond Tutu HIV Foundation","startDate":"2020-05-15","conditions":"Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture","enrollment":102},{"nctId":"NCT05738681","phase":"PHASE2, PHASE3","title":"Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-09-09","conditions":"Tuberculosis, Drug Induced Liver Injury, Hepatitis","enrollment":82},{"nctId":"NCT05202548","phase":"","title":"Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021","status":"COMPLETED","sponsor":"Universitas Katolik Widya Mandala Surabaya","startDate":"2021-05-01","conditions":"Lymphadenitis, Tuberculous, Immune Defect","enrollment":45},{"nctId":"NCT03819114","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-05-06","conditions":"HIV Infections, Tuberculosis","enrollment":122},{"nctId":"NCT02639741","phase":"PHASE4","title":"Preoperative Melatonin or Vitamin C Administration on Postoperative Analgesia","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2014-11","conditions":"Postoperative Pain","enrollment":55},{"nctId":"NCT04043390","phase":"NA","title":"A One-stop Shop for the Same Day Diagnosis and Management of TB and HIV","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2019-01-21","conditions":"Tuberculosis, Hiv","enrollment":1100},{"nctId":"NCT03739736","phase":"","title":"TB Reduction Through ART and TB Screening Project","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-06-12","conditions":"Tuberculosis, HIV/AIDS","enrollment":4200},{"nctId":"NCT02580032","phase":"","title":"Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-05","conditions":"Growth Disorder, Growth Hormone Deficiency in Children","enrollment":252},{"nctId":"NCT04121494","phase":"EARLY_PHASE1","title":"ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)","status":"COMPLETED","sponsor":"François Spertini","startDate":"2019-01-22","conditions":"Mycobacterium Tuberculosis, Protection Against, Tuberculosis","enrollment":39},{"nctId":"NCT03723525","phase":"PHASE4","title":"Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals","status":"COMPLETED","sponsor":"National Centre for AIDs and STD Control, Nepal","startDate":"2018-01-22","conditions":"HIV","enrollment":1073},{"nctId":"NCT04545788","phase":"NA","title":"Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2020-08-01","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT02457637","phase":"","title":"Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study","status":"COMPLETED","sponsor":"Hai Li","startDate":"2015-01-01","conditions":"Liver Failure, Acute on Chronic","enrollment":2600},{"nctId":"NCT03497195","phase":"NA","title":"Achieving Tuberculosis (TB) Control In Zambia","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-07-01","conditions":"Tuberculosis","enrollment":18194},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02538952","phase":"PHASE4","title":"Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-08-01","conditions":"Tuberculosis, Human Immunodeficiency Virus","enrollment":18696},{"nctId":"NCT03800888","phase":"NA","title":"Real-time Tuberculosis Medication Adherence Intervention in Rural Southwestern Uganda","status":"UNKNOWN","sponsor":"Mbarara University of Science and Technology","startDate":"2019-01-10","conditions":"Tuberculosis","enrollment":100},{"nctId":"NCT00707967","phase":"PHASE2","title":"Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-30","conditions":"Tuberculosis","enrollment":37},{"nctId":"NCT01424501","phase":"PHASE2","title":"Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-11-14","conditions":"Tuberculosis","enrollment":142},{"nctId":"NCT03604848","phase":"NA","title":"NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-08-05","conditions":"Multidrug Resistant Tuberculosis","enrollment":488},{"nctId":"NCT03477721","phase":"","title":"The Role of the Muscle-nervous System Interface in Cancer Cachexia","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2018-03-16","conditions":"Cachexia; Cancer; Sarcopenia","enrollment":40},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT02532829","phase":"","title":"Human Intestinal Peptides Evaluation and Research","status":"UNKNOWN","sponsor":"Turkish Metabolic Surgery Foundation","startDate":"2015-09","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":240},{"nctId":"NCT01642888","phase":"PHASE3","title":"A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2012-09","conditions":"Tuberculosis","enrollment":1190},{"nctId":"NCT02497079","phase":"NA","title":"Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2015-07","conditions":"Lymphadenopathy, Tuberculosis, Sarcoidosis","enrollment":100},{"nctId":"NCT01241188","phase":"PHASE2","title":"A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2011-04","conditions":"Tuberculosis","enrollment":253},{"nctId":"NCT01779102","phase":"PHASE2, PHASE3","title":"Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2013-10","conditions":"Tuberculosis","enrollment":456},{"nctId":"NCT01631266","phase":"PHASE3","title":"Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2012-07","conditions":"Tuberculosis","enrollment":979},{"nctId":"NCT01903889","phase":"NA","title":"Male Engagement in PMTCT Services","status":"COMPLETED","sponsor":"FHI 360","startDate":"2013-01","conditions":"HIV","enrollment":3806},{"nctId":"NCT01879163","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-07","conditions":"Tuberculosis (TB)","enrollment":30},{"nctId":"NCT01683773","phase":"PHASE1","title":"Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-09","conditions":"Tuberculosis","enrollment":40},{"nctId":"NCT01033929","phase":"PHASE1","title":"A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2010-01","conditions":"Tuberculosis","enrollment":38},{"nctId":"NCT01242475","phase":"PHASE2","title":"A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2011-04","conditions":"Tuberculosis","enrollment":151},{"nctId":"NCT01194180","phase":"PHASE1","title":"A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-05","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT01315301","phase":"NA","title":"Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2008-08","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":450},{"nctId":"NCT00197704","phase":"PHASE3","title":"Nutrition, Immunology and Epidemiology of Tuberculosis","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2000-03","conditions":"Tuberculosis","enrollment":876},{"nctId":"NCT00170404","phase":"PHASE3","title":"TB Nutrition, Immunology and Epidemiology","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-06","conditions":"Mycobacterium Tuberculosis","enrollment":887},{"nctId":"NCT00293228","phase":"PHASE4","title":"Treatment of Latent Tuberculosis Infection With Isoniazid","status":"COMPLETED","sponsor":"Instituto Nacional de Salud Publica, Mexico","startDate":"2007-02","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT00311298","phase":"PHASE3","title":"Nutrition, Diabetes and Pulmonary TB/HIV","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2006-04","conditions":"Tuberculosis, HIV, Diabetes","enrollment":1250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rdESAT-6 + rCFP-10"],"phase":"phase_3","status":"active","brandName":"C-Tb","genericName":"C-Tb","companyName":"Statens Serum Institut","companyId":"statens-serum-institut","modality":"Biologic","firstApprovalDate":"","aiSummary":"C-Tb is a tuberculosis vaccine candidate that stimulates immune responses against Mycobacterium tuberculosis antigens to prevent or treat tuberculosis infection. Used for Tuberculosis (TB) as adjunctive therapy with standard anti-TB chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}